Circadian rhythms and cancer

Cell Cycle

Volumn 9, Issue 6, 2010, Pages 1097-1103

  Gery, Sigal ^a   Koeffler, H Phillip ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Circadian; Hematopoietic system; Prostate cancer; Tumorigenesis

Indexed keywords

BREAST CANCER; CARCINOGENESIS; CIRCADIAN RHYTHM; COLORECTAL CANCER; ENDOMETRIUM CANCER; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HUMAN; HYPOTHALAMUS; LEUKEMIA; NONHUMAN; OSCILLATION; PANCREAS ADENOCARCINOMA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 77953520230     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.6.11046     Document Type: Review

References (94)

1. Rosato E, Kyriacou CP. Origins of circadian rhythmicity.J Biol Rhythms 2002; 17:506-11.
2. Roenneberg T, Merrow M. Circadian clocks - the fall and rise of physiology. Nat Rev Mol Cell Biol 2005; 6:965-71.
3. Dunlap JC. Molecular bases for circadian clocks. Cell 1999; 96:271-90.
4. Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell 2002; 111:919-22.
5. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418:935-41.
6. Okamura H. Clock genes in cell clocks: roles, actions and mysteries. J Biol Rhythms 2004; 19:388-99.
7. Bell-Pedersen D, Cassone VM, Earnest DJ, Golden SS, Hardin PE, Thomas TL, et al. Circadian rhythms from multiple oscillators: lessons from diverse organisms. Nat Rev Genet 2005; 6:544-56.
8. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008; 9:764-75.
9. Shearman LP, Sriram S, Weaver DR, Maywood ES, Chaves I, Zheng B, et al. Interacting molecular loops in the mammalian circadian clock. Science 2000; 288:1013-9.
10. Mehra A, Baker CL, Loros JJ, Dunlap JC. Posttranslational modifications in circadian rhythms. Trends Biochem Sci 2009; 34:483-90.
11. Belden WJ, Loros JJ, Dunlap JC. CLOCK leaves its mark on histones. Trends Biochem Sci 2006; 31:610-3.
12. Grimaldi B, Nakahata Y, Kaluzova M, Masubuchi S, Sassone-Corsi P. Chromatin remodeling, metabolism and circadian clocks: the interplay of CLOCK and SIRT1. Int J Biochem Cell Biol 2009; 41:81-6.
13. Yagita K, Tamanini F, van Der Horst GT, Okamura H. Molecular mechanisms of the biological clock in cultured fibroblasts. Science 2001; 292:278-81.
14. Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 2004; 119:693-705.
15. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002; 109:307-20.
16. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature 2002; 417:78-83. (Pubitemid 34498819)
17. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003; 4:649-61.
18. Chen YG, Mantalaris A, Bourne P, Keng P, Wu JH. Expression of mPer1 and mPer2, two mammalian clock genes, in murine bone marrow. Biochem Biophys Res Commun 2000; 276:724-8.
19. Smaaland R, Sothern RB, Laerum OD, Abrahamsen JF. Rhythms in human bone marrow and blood cells. Chronobiol Int 2002; 19:101-27. (Pubitemid 34326438)
20. Boivin DB, James FO, Wu A, Cho-Park PF, Xiong H, Sun ZS. Circadian clock genes oscillate in human peripheral blood mononuclear cells. Blood 2003; 102:4143-5.
21. + cells. J Biol Rhythms 2007; 22:140-50.
22. Fukuya H, Emoto N, Nonaka H, Yagita K, Okamura H, Yokoyama M. Circadian expression of clock genes in human peripheral leukocytes. Biochem Biophys Res Commun 2007; 354:924-8.
23. th dimension and adult stem cells: Can timing be everything? J Cell Biochem 2009 10:569-78.
24. Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, et al. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J 2005; 19:304-6.
25. Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452:442-7.
26. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002; 111:41-50.
27. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science 2003; 302:255-9.
28. Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HY, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 2006; 97:1298-307.
29. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler H. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 2005; 106:2827-36.
30. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, et al. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res 2009; 69:3605-13.
31. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 2007; 120:432-5.
32. Lahti TA, Partonen T, Kyyrönen P, Kauppinen T, Pukkala E. Night-time work predisposes to non-Hodgkin lymphoma. Int J Cancer 2008; 123:2148-51.
33. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009; 27:619-28.
34. Bozek K, Relógio A, Kielbasa SM, Heine M, Dame C, Kramer A, et al. Regulation of clock-controlled genes in mammals. PLoS One 2009; 4:4882.
35. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 2009; 15:151-8.
36. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, et al. The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008 134:329-40.
37. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, Kreppel F, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 2008; 134:317-28.
38. Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, et al. Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci USA 2007; 104:3342-7.
39. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One 2009; 4:4798.
40. Maier B, Wendt S, Vanselow JT, Wallach T, Reischl S, Oehmke S, et al. A large-scale functional RNAi screen reveals a role for CK2 in the mammalian circadian clock. Genes Dev 2009; 23:708-18.
41. Baker CL, Kettenbach AN, Loros JJ, Gerber SA, Dunlap JC. Quantitative proteomics reveals a dynamic interactome and phase-specific phosphorylation in the Neurospora circadian clock. Mol Cell 2009; 34:354-63.
42. Sathyanarayanan S, Zheng X, Kumar S, Chen CH, Chen D, Hay B, et al. Identification of novel genes involved in light-dependent CRY degradation through a genome-wide RNAi screen. Genes Dev 2008; 22:1522-33. (Pubitemid 351793086)
43. Baggs JE, Price TS, DiTacchio L, Panda S, Fitzgerald GA, Hogenesch JB. Network features of the mammalian circadian clock. PLoS Biol 2009; 10:7-52.
44. Zhang EE, Liu AC, Hirota T, Miraglia LJ, Welch G, Pongsawakul PY, et al. A Genome-wide RNAi Screen for Modifiers of the Circadian Clock in Human Cells. Cell 20092; 139:199-210.
45. Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 2007; 47:593-628. (Pubitemid 46272140)
46. Lévi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 2006; 17:611-21.
47. Lucas D, Battista M, Shi PA, Isola L, Frenette PS. Mobilized hematopoietic stem cell yield depends on species-specific circadian timing. Cell Stem Cell 2008; 3:364-6.
48. D'Hondt L, McAuliffe C, Damon J, Reilly J, Carlson J, Dooner M, et al. Circadian variations of bone marrow engraftability. J Cell Physiol 2004; 200:63-70. (Pubitemid 38720622)
49. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113:6215-24.
50. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113:6206-14.
51. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci USA 2005; 102:3407-12.
52. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 2001; 12:74-7.
53. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001; 93:1563-8.
54. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001; 93:1557-62.
55. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. Natl Cancer Inst 2003; 95:825-8.
56. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer 2005; 41:2023-32.
57. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol 2006; 164:549-55.
58. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007; 67:10618-22.
59. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 2005; 26:1241-6.
60. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia 2007; 9:797-800. (Pubitemid 47623419)
61. Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, Hsu NC, et al. Disturbance of circadian gene expression in breast cancer. Virchows Arch 2009; 454:467-74.
62. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
63. Bebas P, Goodall CP, Majewska M, Neumann A, Giebultowicz JM, Chappell PE. Circadian clock and output genes are rhythmically expressed in extratesticular ducts and accessory organs of mice. FASEB J 2009; 23:523-33.
64. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP. A role for the clock gene, Per1 in prostate cancer. Cancer Res 2009; 69:7619-25.
65. Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis 2008; 11:342-8.
66. Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat 2008; 107:421-5.
67. Yi C, Mu L, de la Longrais IA, Sochirca O, Arisio R, Yu H, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer. Breast Cancer Res Treat 2009.
68. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007; 26:7916-20.
69. Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ. Downregulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 2009; 117:423-31.
70. Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006; 126:801-10. (Pubitemid 44233631)
71. Teboul M, Gréchez-Cassiau A, Guillaumond F, Delaunay F. How nuclear receptors tell time. J Appl Physiol 2009; 107:1965-71.
72. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006 125:497-508.
73. Belden WJ, Dunlap JC. SIRT1 is a circadian deacetylase for core clock components. Cell 2008; 134:212-4.
74. Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila J, et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 2008; 456:997-1000.
75. Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, et al. Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 2006; 26:8122-35.
76. Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 2007; 21:1807-21.
77. Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol 2002; 16:1492-501.
78. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y, et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 2008; 373:423-8.
79. Ravindra T, Lakshmi NK, Ahuja YR. Melatonin in pathogenesis and therapy of cancer. Indian J Med Sci 2006; 60:523-35.
80. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30:118-28.
81. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther 2008; 7:189-203.
82. Antoch MP, Gorbacheva VY, Vykhovanets O, Toshkov IA, Kondratov RV, Kondratova AA, et al. Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle 2008; 7:1197-204.
83. Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1, the core componentof the circadian clock. Genes Dev 2006; 20:1868-73.
84. Min/+ tumorigenesis. Mol Cancer Res 2008; 6:1786-93.
85. Ozturk N, Lee JH, Gaddameedhi S, Sancar A. Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci USA 2009; 106:2841-6.
86. Shih MC, Yeh KT, Tang KP, Chen JC, Chang JG. Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 2006; 45:732-40.
87. Krugluger W, Brandstaetter A, Kállay E, Schueller J, Krexner E, Kriwanek S, et al. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 2007; 67:7917-22.
88. Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 2007; 13:1399-404.
89. Eisele L, Prinz R, Klein-Hitpass L, Nückel H, Lowinski K, Thomale J, et al. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 2009.
90. Penas EM, Cools J, Algenstaedt P, Hinz K, Seeger D, Schafhausen P, et al. A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene. Genes Chromosomes Cancer 2003; 37:79-83. (Pubitemid 36417924)
91. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Gréchez- Cassiau A, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res 2004; 64:7879-85.
92. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002; 94:690-7.
93. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000; 92:994-1000. (Pubitemid 30469965)
94. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, et al. Chronotherapy Group of the European Organization for Research and Treament of Cancer. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 2009; 69:4700.